



Accelerating the Hepatitis C Care Cascade for Patients with Substance Use

Rienstra J, Schiller K, Battle R, Chantrill A, Iwasaki J
Lummi Tribal Health Center



Disclosures

- None



Background/aims

- 80% of our HCV population have current or historic substance use disorder.
- Patients with current substance use disorder require a healthcare delivery model that matches their needs.
- Our healthcare delivery model accelerates HCV treatment initiation from 6-8 months to 2-4 weeks.

Methods

- Screening campaigns using point of care testing
- Comprehensive screening (HCV RNA with RFLX to Genotype, LFTs, Acute Hep Panel, CBC, BMP, PT/INR, onsite Fibroscan)
- Collaboration with alternative contact points
- Patient led treatment delivery plan
- Robust Case Management
- Syringe Service Program harm reduction education/supplies to reduce transmission.

Results

- Screened 1,861 of 5,775 (32%) adult patients
- Screened 188 of the 331 (57%) patients in the opioid treatment program
- Identified 151 chronic HCV patients
- Treatment completed 77 of 151 (51%) chronic HCV patients
- Resulted in 100% treatment success by aligning programs to each patient's unique needs

Conclusions/implications

With multidisciplinary collaboration, onsite fibroscan allowing streamlined linkage to medication, patient engagement in developing care delivery plans, and continuing to foster a therapeutic environment for those with addiction as a chronic disease, HCV elimination becomes a realistic possibility for the Lummi Nation.

Acknowledgements

Special thanks to:

NPAlHB Jessica Leston and David Stephens for promoting innovative HCV treatment at the primary care level

Dr. Jorge Mera and Whitney Essex ARNP for their availability to guide our treatment with specialist recommendations through ECHO teleconferences

Thank you to INHSU for continued championing of all patient's rights and access to health care